TABLE 1.
Association between ALI and clinicopathological factors
| Characteristics |
Overall n = 813 |
ALI‐high n = 532 |
ALI‐low n = 281 |
P value a |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Sex | ||||
| Male | 464 (57%) | 219 (41%) | 245 (87%) | <.001 |
| Female | 349 (43%) | 313 (59%) | 36 (13%) | |
| Age | ||||
| <65 | 291 (36%) | 206 (39%) | 85 (30%) | .016 |
| ≥65 | 522 (64%) | 326 (61%) | 196 (70%) | |
| BMI (kg/m2) | ||||
| <18.5 | 95 (12%) | 54 (10%) | 41 (15%) | <.001 |
| 18.5≤, <25 | 536 (66%) | 328 (62%) | 208 (74%) | |
| ≥25 | 182 (22%) | 150 (28%) | 32 (11%) | |
| Tumor location | ||||
| Right side | 264 (32%) | 161 (30%) | 103 (37%) | .065 |
| Left side | 549 (68%) | 371 (70%) | 178 (63%) | |
| Depth of tumor invasion | ||||
| T1 | 198 (24%) | 154 (29%) | 44 (16%) | <.001 |
| T2 | 160 (20%) | 115 (22%) | 45 (16%) | |
| T3 | 342 (42%) | 205 (38%) | 137 (49%) | |
| T4 | 113 (14%) | 58 (11%) | 55 (19%) | |
| Lymph node metastasis | ||||
| Negative | 580 (71%) | 372 (70%) | 205 (73%) | .364 |
| Positive | 233 (29%) | 160 (30%) | 76 (27%) | |
| Stage | ||||
| I | 307 (38%) | 226 (43%) | 81 (29%) | <.001 |
| II | 274 (34%) | 149 (28%) | 125 (44%) | |
| III | 232 (28%) | 157 (29%) | 75 (27%) | |
| CEA (ng/mL) | ||||
| ≤5 | 590 (73%) | 412 (77%) | 178 (63%) | <.001 |
| >5 | 223 (27%) | 120 (23%) | 103 (37%) | |
| CA19‐9 (U/mL) | ||||
| ≤37 | 685 (84%) | 451 (85%) | 234 (83%) | .578 |
| >37 | 128 (16%) | 81 (15%) | 47 (17%) | |
Abbreviations: ALI, advanced lung cancer inflammation index; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen.
a
P value was based on the chi‐square test for categorical factors.